Table 2.
Demographic Characteristics of 124 IMD patients infected with COVID-19.
| Demographic and clinical data | Number (%) | Comment |
|---|---|---|
| Age group | ||
| <16 years | 56 (45%) | Asymptomatic 12 (21.4%); Mild 36 (64%); Mod- severe 8 (14%) |
| >16 years | 68 (55%) | Asymptomatic 5 (7.4%); Mild 49 (72%); Mod- severe 14 (20.5%) |
| Gender | ||
| Male | 71 (57%) | |
| Female | 53 (43%) | |
| IMD Diagnostic category | ||
| Intoxication disorders | 82 (65%) | Hospitalized 16 (20%) |
| Carbohydrate metabolism defects | 22 (18%) | Hospitalized 0 |
| Energy metabolism defects | 18 (14.5%) | Hospitalized 4 (22%) |
| Complex molecules defects | 3 (2.5%) | Hospitalized 2 (67%) |
| Reason for COVID-19 PCR test | ||
| Post-exposure screening | 97 (78) | |
| Diagnostic (symptomatic) | 24 (19) | |
| Pre-hospital visit screening | 3 (2.5) | |
| COVID-19 Symptoms | ||
| Asymptomatic | 17 (13.7%) | Pediatrics 12 (70%), adults 5 (30%) |
| Symptomatic with COVID-19 related infection | 107 (86.3%) | |
| Metabolic Complications frequency | ||
| Metabolic acidosis | 14 (11%) | ((MMA (n = 7); PA (n = 3); HMG (n = 2); ASA (n = 2)) |
| Hyperammonemia | 5 (4%) | (PA (n = 3); ASA (n = 2)) |
| Acute pancreatitis | 2 (1.6%) | ((PA (n = 1); ASA (n = 1)) |
| Rhabdomyolysis | 2 (1.6%) | (VLCADD (n = 2)) |
| Acute liver impairment | 2 (1.6%) | ((ASA n = 1);VLCADD (n = 1)) |
| Hypoglycemia | 2 (1.6%) | (VLCADD (n = 1)) |
| Thrombosis | 1 (0.8%) | (HCU (n = 1)) |
| Management and Outcome | ||
| Home management | 102 (69%) | |
| Hospitalization | 22 (18%) | |
| Intensive care | 10 (8%) | See Table 3 for details |
| Deaths | 3 (2.4%) | |